Norgine Limited was founded in 1906 and is based in Harefield, the United Kingdom with regional offices in Tunisia and Saudi Arabia. It has manufacturing sites in Dreux, France; and Hengoed, the United Kingdom. The company has subsidiaries in the United Kingdom, France, Germany, Belgium, the Netherlands, Denmark, Switzerland, Austria, Italy, and Spain, as well as in Australia, and South Africa. Norgine Limited is a subsidiary of Norgine Europe B.V. Norgine Limited, a specialty pharmaceutical company, develops, manufactures, and markets products in the areas of gastroenterology, hepatology, and pain management in Europe. It offers products for the treatment of chronic constipation and faecal impaction, bowel preparation prior to colonoscopy, ulcerative colitis, Crohn's disease, duodenal and benign gastric ulcers, traveler’s diarrhoea, and pain, as well as provides antitussive medications and products for the relief of smooth muscle spasm. The company also provides assistance in the development and launch of pharmaceutical products for companies.

BioMS Medical Corp. was founded in 1998 and is headquartered in Edmonton, Canada. BioMS Medical Corp., a development stage biotechnology company, through its subsidiaries, engages in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS) in Canada. Its lead product under development includes Dirucotide for the treatment of multiple sclerosis, which is being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients; and MAESTRO-01, a pivotal phase II/III trial in Canada and western Europe. The company also develops Maestro-02, an open-label follow-on study to the Maestro-01 pivotal phase II/III clinical trial of Dirucotide, which targets secondary progressive multiple sclerosis (SPMS), as well as MAESTRO-03 trial, a pivotal Phase III product to evaluate the safety and efficacy of Dirucotide in patients with SPMS in the United States. BioMS Medical Corp. has a licensing and development agreement with Eli Lilly and Company. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in July 2001.

Herborium Group is a developer and marketer of herbal nutritional supplements. Herborium's product line includes Traditional Chinese Medicine herbal blends designed to clear up acne (AcnEase), boost energy (Energy Restoration), and heighten sexual performance (Lasting Pleasure for women, MaleForce for men). Herborium sells it products in the US, the UK, and continental Europe through a network of distributors, specialty retailers, such as natural foods stores, and online marketplaces. The company's founder, president and CEO Agnes Olszewski and director James Gilligan hold about 70% of the company's shares.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Banner Pharmacaps, Inc., a drug delivery and specialty pharmaceutical company, engages in the research, development, and manufacture of oral dosage forms for the pharmaceutical health care industry. It develops drug delivery systems and patented technologies, including Soflet Gelcaps, a technology that enrobes tablets with a gelatin or non-animal film; LiquiSoftT Chewable Liquid-Filled Softgels, which is a chewable gel dosage form suitable for pediatric populations; Chewel, a soft chewable gelatin dosage form for pediatric populations; EnteriCare, which are enteric softgels; Versatrol, which is a controlled release softgel technology; and EcoCaps, which are non-animal softgels. It serves pharmaceutical and biotechnology, and consumer healthcare markets. The company was founded in 1994 and is headquartered in High Point, North Carolina. It has drug manufacturing facilities in High Point, North Carolina; Tilburg, the Netherlands; Olds, Canada; and Mexico City, Mexico. It has locations in Mexico, Europe, the Asia/Pacific, the United States, and Canada. Banner Pharmacaps, Inc. operates as a subsidiary of VION N.V.

Calyx Bio-Ventures (formerly Chromos Molecular Systems) wants you to part with that chromosome. The company is developing therapeutic products to fight diseases based on its REM (rapid expansion method) technology. The company has sold its ACE System (artificial chromosome expression) technology but retains some rights to use the ACE System for gene therapy applications. The system's potential biopharmaceutical product applications include therapies for infectious diseases and cancers. The company emerged from bankruptcy protection in late 2007 and completed its restructuring when it merged its operations into its Calyx subsidiary the following year.

AstraZeneca France does its bit to help its parent, global pharmaceutical powerhouse AstraZeneca, fight diseases from A to Z. In addition to its headquarters at Reuil Malmaison, the company operates an R&D facility for cancer treatments and packaging in Reims. The plant, which produces cancer as well as cardiovascular drugs, sends about a third of its product to Italy, the rest to North Africa and Portugal. The company's Dunkirk production plant makes Pulmicort, Symbicort, Mopral, and INexium in its chemical unit, while the pharmaceutical unit makes Bricanyl and Turbuhaler. Dunkirk ships its finished products to the US. In all AstraZeneca France, which was formed in 1975, makes and ships about 40 drugs.

Apotex Inc. company is Canada's leading generic drugmaker, producing some 300 generic drugs in thousands of varying dosages and formulations. Its product line includes generic equivalents of Merck's Claritin (allergy medication) and Pfizer's Norvasc (hypertension). Apotex markets its drugs throughout Canada and the US, as well as in about 115 other countries in the Asia/Pacific region, Africa, Europe, Latin America, and the Middle East. Apotex company also has a manufacturing agreement with The Harvard Drug Group.

ZymoGenetics, Inc. company was founded in 1981 and is headquartered in Seattle, Washington. ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The company's product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein, which is in Phase Ib clinical trials for the treatment of viral infections and autoimmune diseases; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases. Its out-licensed product candidates include atacicept for the treatment of systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; Augment Bone Graft for orthopedic fracture and other bone defects; rFactor XIII for congenital factor XIII deficiency, cardiac surgery, and cancer related bleeding; Fibroblast growth factor-18 for osteoarthritis; IL-17 receptor C for inflammatory diseases; and IL-20 and IL-22 receptor subunit alpha for psoriasis. The company also offers out-licensed commercial products comprising Novolin and insulin analogs for diabetes; NovoSeven for the treatment of hemophilia; Regranex for wound healing; GEM 21S for periodontal defects; GlucaGen for hypoglycemia and gastrointestinal motility inhibition; and Cleactor for treatment of myocardial infarction. ZymoGenetics has collaboration agreements with Bayer Schering Pharma AG; Bristol-Myers Squibb Company; and Merck Serono S.A.

Merck was founded in 1668 as a pharmacy and is the oldest pharmaceutical business in the world. The Merck family owns about 70% of the company. Merck is leaving its mark on the global pharmaceutical market. Through a network of nearly 200 companies in over 60 countries, the Merck develops, makes, and sells pharmaceutical and chemical products for global consumption. Name-brand prescription drugs include treatments for cardiovascular disease, cancers, infertility, and neurological disorders; the company also makes over-the-counter pharmaceuticals. Aside from drugs, the firm makes specialty chemicals, including laboratory reagents and cosmetic ingredients, as well as liquid crystals for televisions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.